{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:36:36Z","timestamp":1791048996165,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4265,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1093\/annonc\/mdm510","type":"journal-article","created":{"date-parts":[[2007,12,3]],"date-time":"2007-12-03T20:59:28Z","timestamp":1196715568000},"page":"807-813","source":"Crossref","is-referenced-by-count":81,"title":["Compassionate use of bevacizumab (Avastin\u00ae) in children and young adults with refractory or recurrent solid tumors"],"prefix":"10.1016","volume":"19","author":[{"given":"M.","family":"Benesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Windelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Sauseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fleischhack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gadner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm510_bb0010","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.ejca.2006.05.006","article-title":"Trends in survival after childhood cancer in Europe. 1978\u20131997: report from the Automated Childhood Cancer Information System project (ACCIS)","volume":"42","author":"Magnani","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm510_bb0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pbc.20726","article-title":"Survival after relapse in children with solid tumors: a follow-up study from the Italian Off-Therapy Registry","volume":"47","author":"Ceschel","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1093\/annonc\/mdm510_bb0020","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2005.05.105","article-title":"Survival after recurrence of Ewing\u2019s sarcoma family of tumors","volume":"23","author":"Barker","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","article-title":"Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group","volume":"23","author":"Kempf-Bielack","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0030","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1200\/JCO.1999.17.11.3487","article-title":"Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group","volume":"17","author":"Pappo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0035","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.bjc.6603402","article-title":"Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas","volume":"95","author":"Wagner","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm510_bb0040","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1634\/theoncologist.11-9-981","article-title":"Therapy for metastatic colorectal cancer","volume":"11","author":"Goldberg","year":"2006","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm510_bb0045","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/cncr.21453","article-title":"Targeted therapy for the treatment of advanced renal cell carcinoma","volume":"104","author":"Stadler","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm510_bb0050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1634\/theoncologist.9-4-357","article-title":"Molecularly targeted therapy: have the floodgates opened?","volume":"9","author":"Druker","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm510_bb0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2003.08.022","article-title":"VEGF and HIF-1\u03b1 expression are increased in advanced stages of epithelial ovarian cancer","volume":"91","author":"Wong","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10434-001-0072-y","article-title":"Vascular-endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis","volume":"8","author":"Han","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1093\/annonc\/mdm510_bb0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1093\/annonc\/mdm510_bb0075","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm510_bb0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm510_bb0085","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0090","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0095","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdm510_bb0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1359-6349(06)80030-3","article-title":"A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern Cooperative Oncology Group trial E2100","volume":"4","author":"Zon","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm510_bb0105","first-page":"368","article-title":"Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors","volume":"146","author":"Hatva","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdm510_bb0110","first-page":"763","article-title":"Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas","volume":"148","author":"Hatva","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdm510_bb0115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0959-8049(98)00387-6","article-title":"Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma","volume":"35","author":"Meister","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm510_bb0120","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1038\/sj.onc.1208939","article-title":"Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid","volume":"24","author":"Gee","year":"2005","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdm510_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jcp.56.2.107","article-title":"Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma","volume":"56","author":"Ghanem","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdm510_bb0130","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/1078-0432.CCR-04-1201","article-title":"Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing\u2019s sarcoma family","volume":"11","author":"Dalal","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm510_bb0135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1203\/01.pdr.0000242494.94000.52","article-title":"The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts","volume":"60","author":"Segerstr\u00f6m","year":"2006","journal-title":"Pediatr Res"},{"key":"10.1093\/annonc\/mdm510_bb0140","article-title":"Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (Avastin) induce regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy","author":"Joshi","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"Suppl 18","key":"10.1093\/annonc\/mdm510_bb0145","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/jco.2006.24.18_suppl.9017","article-title":"A phase I study of bevacizumab in children with refractory solid tumors: a Children's Oncology Group study","volume":"24","author":"Glade Bender","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"10.1093\/annonc\/mdm510_bb0150","doi-asserted-by":"crossref","first-page":"11522","DOI":"10.1200\/jco.2006.24.18_suppl.11522","article-title":"Combination of bevacizumab, a monocloncal antibody to vascular endothelial growth factor (VEGF), and temozolomide: study of cases","volume":"24","author":"Kirkpatrick","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm510_bb0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02484282","article-title":"Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas","volume":"17","author":"Miyagami","year":"2000","journal-title":"Brain Tumor Pathol"},{"key":"10.1093\/annonc\/mdm510_bb0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2006.09.016","article-title":"The impact of the \u2018Clinical Trials\u2019 directive on the cost and conduct of non-commercial cancer trials in the UK","volume":"43","author":"Hearn","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm510_bb0165","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(07)60797-1","article-title":"The EU Clinical Trials Directive: 3 years on","volume":"369","author":"Hoey","year":"2007","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419414397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419414397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/4\/807\/579247\/mdm510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T23:33:36Z","timestamp":1588116816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419414397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0923753419414397"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm510","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}